METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for resistant prostate cancer falls short
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combination was safe and could delay cancer …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control TerminatedThis study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals were …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Promising prostate cancer treatment trial halted early
Disease control TerminatedThis study tested a new drug (177Lu-DOTA-rosopatamab) that delivers radiation directly to prostate cancer cells. It was for men with advanced prostate cancer that had stopped responding to hormone therapy. The trial aimed to see if adding this drug to standard care could slow can…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
Prostate cancer imaging drug showdown ends early
Knowledge-focused TerminatedThis early-stage study aimed to compare two radioactive drugs (lutetium rhPSMA-10.1 and Pluvicto) in 17 men with advanced prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors while sparing the kidneys. The study was terminated ear…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Knowledge-focused
Last updated May 04, 2026 16:18 UTC